Biomark Diagnostics (XCNQ:BUX) ROCE % : 0.00% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biomark Diagnostics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biomark Diagnostics's annualized ROCE % for the quarter that ended in Dec. 2024 was 0.00%.

Biomark Diagnostics ROCE % Historical Data

The historical data trend for Biomark Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics ROCE % Chart

Biomark Diagnostics Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-140,400.00

Biomark Diagnostics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Biomark Diagnostics ROCE % Calculation

Biomark Diagnostics's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	-1.312	/	( ( (0.732 - 1.664)	+	(1.089 - 1.244) )	/ 2 )
	=	-1.312	/	( (-0.932	+	-0.155)	/ 2 )
	=	-1.312	/	-0.5435
	=	241.40 %

Biomark Diagnostics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-1.28	/	( ( (0.878 - 1.458)	+	(0.877 - 1.52) )	/ 2 )
	=	-1.28	/	( ( -0.58	+	-0.643 )	/ 2 )
	=	-1.28	/	-0.6115
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Biomark Diagnostics (XCNQ:BUX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biomark Diagnostics ROCE % Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomark Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (XCNQ:BUX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BMKDF:USA 20B:Germany

Address

130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2

Website

https://www.biomarkdiagnostics.com

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.

Executives

Guoyu Huang	Senior Officer
Rashid Ahmed Maula Bux	Director

Biomark Diagnostics Headlines

No Headlines